Hybrid Analogues Research Articles

α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both invitro and invivo.

Peptides are increasingly important resources for biological and therapeutic development, however, their intrinsic susceptibility to proteolytic degradation represents a big hurdle. As a natural agonist for GLP-1R, glucagon-like peptide 1 (GLP-1) is of significant clinical interest for the treatment of type-2 diabetes mellitus, but its invivo instability and short half-life have largely prevented its therapeutic application. Here, we describe the rational design of a series of α/sulfono-γ-AA peptide hybrid analogues of GLP-1 as the GLP-1R agonists. Certain GLP-1 hybrid analogues exhibited enhanced stability (t 1/2>14 days) compared to t 1/2 (<1 day) of GLP-1 in the blood plasma and invivo. These newly developed peptide hybrids may be viable alternative of semaglutide for type-2 diabetes treatment. Additionally, our findings suggest that sulfono-γ-AA residues could be adopted to substitute canonical amino acids residues to improve the pharmacological activity of peptide-based drugs.

Synthesis, in vitro bio-evaluation, and molecular docking study of thiosemicarbazone-based isatin/bis-Schiff base hybrid analogues as effective cholinesterase inhibitors

Analogues of isatin/bis-Schiff bases based on thiocarbohydrazone (1–16) were synthesized, characterised using various methods like NMR and HR-ESI-MS, and then tested against the acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes. All analogues showed good inhibitory potentials ranging from 0.20 ± 0.05 to 7.40 ± 0.20 M (for AChE) and 0.50 ± 0.05 to 9.40 ± 0.10 M (for BuChE) as compared to the reference drug Donepezil (IC50 = 2.16 ± 0.12 & 4.5 ± 0.11 M respectively). Analogue 1 was shown to be the most effective inhibitor of the AChE and BuChE enzymes among the synthesised analogues. The reason for Analogue 1 may be due to the role played by oxygen and the nitro motif in H-bonding with the active sites of AChE and BuChE enzymes. A structure–activity relationship (SAR) was developed based on nature, position, number, and the electron-donating and -withdrawing effects of substitution(s) on phenyl rings. Molecular docking studies were used to describe the binding interactions of the most active inhibitors with the active sites of AChE and BuChE.

Ultrasound-assisted green synthesis of triazole-based azomethine/thiazolidin-4-one hybrid inhibitors for cancer therapy through targeting dysregulation signatures of some Rab proteins

ABSTRACT The overexpression of Rab proteins was linked to cancer development, making this family of proteins an attractive drug target for the identification of novel inhibitors against tumor diseases. In this study, novel triazole-based azomethine/thiazolidin-4-one hybrid analogs were designed, prepared and structurally confirmed by using elemental and spectral techniques, these include FT-IR, MS, and NMR spectra. In addition, in vitro cytotoxic activity was assessed against NCI-60 cancer cell lines. To understand the possible mode of action and drugability, molecular docking studies and drug-likeness were achieved. The docking simulations were performed against various Rab family proteins Rab2a, Rab25, Rab5, and Rab35; promising targets for cancer medication to support the cytotoxicity findings and to further validate the action of new molecules. Furthermore, in silico ADMET screening of the molecules was within the recommended values stated by Lipinski's rule of five (Ro5), indicating their oral bioavailability and therapeutic potentials. Among the newly prepared analogs tested, compounds 4d and 3d exhibited significant antitumor activity against breast, ovarian, lung, and leukemia cancer cell lines. Our findings suggested that azomethine/thiazolidin-4-one moieties incorporated triazole analogs are a promising class of molecular entities for the development of new anticancer therapies, through targeting of some Rab proteins.

Peptoid-Peptide Hybrid Analogs of the Enterococcus faecalis Fsr Auto-Inducing Peptide (AIP) Reveal Crucial Structure-Activity Relationships.

As multidrug-resistant bacteria become a more pressing risk to human health, alternate approaches to treating bacterial infections are being increasingly investigated. Enterococcus faecalis is an opportunistic pathogen responsible for a large percentage of secondary enterococci infections. Its pathogenicity has been shown to be largely dependent on a cell-density communication mechanism, termed quorum sensing. In this study, we conducted a systematic investigation of the lactone-containing macrocyclic signaling peptide used by E. faecalis for Fsr-mediated communication, termed gelatinase biosynthesis activating pheromone (GBAP). Specifically, through a combination of the on-resin sub-monomer and solution phase peptoid building block synthesis approaches, we successfully synthesized a library of peptoid-peptide hybrid analogs of GBAP and determined the biological effects associated with the introduction of the peptoid (N-alkyl glycine derivative) modifications. Within the macrocycle region of the peptide, as have been seen with other modifications, the F7 site was unusually tolerant toward peptoid modification, compared with other macrocyclic sites. Interestingly, within the exocyclic tail, peptoid modification at the N2 site completely abolished activity, a first for a single tail modification.

Benzoxazole based thiazole hybrid analogs: Synthesis, in vitro cholinesterase inhibition, and molecular docking studies

Acetylcholinesterase and butyrylcholinesterase enzymes are therapeutic target for Alzheimer disease and their inhibitors play a vital role for the treatment of this disease. A new series of benzoxazole based 1,3-thiazole hybrid scaffolds (1–20) were synthesized and assessed for acetylcholinesterase and butyrylcholinesterase inhibition profile and then characterized by using different spectroscopic tools such as 1H NMR, 13C NMR and HREI-MS spectroscopy. Four scaffolds such as 1, 4, 12 and 19 showed AChE potency almost comparable to standard drug having IC50 values 0.692 ± 0.087, 0.947 ± 0.089, 0.38 ± 0.016 and 0.742 ± 0.042 µM, while nine scaffolds such as 1, 4, 6, 8, 9, 12, 13, 14 and 19 showed superior BuChE potency than standard drug having IC50 values 2.54 ± 0.10, 1.79 ± 0.20, 3.25 ± 0.18, 2.48 ± 0.05, 1.33 ± 0.05, 2.19 ± 0.08, 2.81 ± 0.20, 2.23 ± 0.10 and 2.10 ± 0.05 µM respectively. Nonetheless, remaining analogs were found to have moderate activity. Among the synthesized series, analogs 12 (IC50 = 0.38 ± 0.016 µM) and 9 (IC50 = 1.33 ± 0.05 µM) were identified as the most potent inhibitors of acetylcholinesterase and butyrylcholinesterase enzymes. In addition, the molecular docking studies were carried out to find out the possible binding mode of interactions of most active analogs with enzymes active site and results supported the experimental data.

Molecular modelling, synthesis and in vitro evaluation of quinazolinone hybrid analogues as potential pancreatic lipase inhibitors

Obesity is a multifactorial metabolic disorder, growing in an alarming rate across the world. Amongst the numerous targets explored for obesity management, inhibition of pancreatic lipase (PL) is considered as one of the promising approaches. Orlistat is the only PL inhibitory drug approved for long term treatment of obesity. However, it is reported to possess hepatotoxicity and nephrotoxicity. Thus, novel drug candidates that act through PL inhibition are considered the hour’s need. Based on this aim, a series of quinazolinone hybrid analogues have been synthesized, characterized and evaluated for their PL inhibitory potential. The physicochemical properties and toxicity parameters suggested that these parameters are in an acceptable range for the screened analogues. Amongst the synthesised analogues, QH-25 exerted potential PL inhibition (IC50 = 16.99 ± 0.54 µM). Further, enzyme inhibition studies suggested a reversible competitive inhibition. Molecular docking of these analogues was in line with in vitro results, wherein the obtained MolDock scores exhibited a significant correlation with their inhibitory activity (Pearson’s r = 0.6629). To further confirm the stability of the QH-25-PL complex in a dynamic environment, a molecular dynamics study (100 ns) was carried out and the results suggested that this complex is stable at dynamic conditions. Overall, these results shed light on the quinazolinone hybrids as potential PL inhibitors. Further structural modification may result in the development of potent anti-obesity agents which acts through PL inhibition. Communicated by Ramaswamy H. Sarma

Design and Synthesis of Echitamine-inspired Hybrid Analogues Containing Thiazolidinediones as Potential Pancreatic Lipase Inhibitors

Background: Obesity is a multifactorial metabolic disease characterised by excessive accumulation of triglycerides. The prevalence and morbidity rates associated with obesity are increasing tremendously, posing a significant risk to society. Pancreatic lipase (PL) is a key enzyme responsible for the digestion of dietary triglycerides; hence its inhibition is considered an attractive target in obesity. Methods: In this present work, a new series of echitamine-inspired indole-based thiazolidinedione hybrid analogues were designed, synthesized, and evaluated for their in vitro PL inhibitory potential. The nature of inhibition has been identified by enzyme kinetic analysis, whereas in silico molecular modelling tools (molecular docking and dynamic studies) were used for the identification of the mode of action at the catalytic site of PL (PDB ID: 1LPB). Fluorescence quenching was used for the identification of the interaction between the potent analogues with PL. Results: The condensation reaction of substituted indole derivatives with TZD in the presence of aqueous KOH resulted in the formation of the titled analogues. Analogues 7k and 7p displayed a potential PL inhibitory activity (IC50 = 11.36 and 11.87 μM, respectively). A competitive mode of PL inhibition was revealed in the enzyme kinetic analysis. A static quenching mechanism was exhibited by the screened agents on PL. The obtained MolDock scores were aligned with the in vitro PL inhibitory activity (Pearson’s r - 0.7575, p &lt; 0.05). Moreover, the PL-ligand complexes were stable in the dynamic conditions. Conclusion: Analogue 7k exerted the potential activity, and further studies might result in novel lead molecules.

Synthesis, In Vitro Biological Evaluation and In Silico Molecular Docking Studies of Indole Based Thiadiazole Derivatives as Dual Inhibitor of Acetylcholinesterase and Butyrylchloinesterase.

The current study was conducted to obtain hybrid analogues of indole-based thiadiazole derivatives (1-16) in which a number of reaction steps were involved. To examine their biological activity in the presence of the reference drug Donepezil (0.21 ± 0.12 and 0.30 ± 0.32 M, respectively), the inhibitory potentials of AChE and BuChE were determined for these compounds. Different substituted derivatives showing a varied range of inhibitory profiles, when compared to the reference drug, analogue 8 was shown to have potent activity, with IC50 values for AchE 0.15 ± 0.050 M and BuChE 0.20 ± 0.10, respectively, while other substituted compounds displayed good to moderate potentials. Varied spectroscopic techniques including 1H, 13CNMR and HREI-MS were used to identify the basic skeleton of these compounds. Furthermore, all analogues have a known structure-activity relationship (SAR), and molecular docking investigations have verified the binding interactions of molecule to the active site of enzymes.

Discovery of oxazoline-triazole based hybrid molecules as DNA gyrase inhibitors: A new class of potential Anti-tubercular agents

A library of novel oxazoline-triazole hybrid analogues (6a-6 g and 7a-7 m)was designed using a molecular hybridization approach and synthesized from commercially available ethyl 2/3/4-hydroxybenzoate. The synthesized compounds were characterized by modern art instrumentation, including IR and NMR (1H, 13C). All the final compounds were evaluated for their in-vitro antibacterial (S. aureus, B. subtilis, E. coli and P. aeruginosa), antifungal (C. neoformans, C. albicans and A. niger) and anti-tubercular (Mycobacterium tuberculosis H37Rv, MDR and XDR strains) activities. Among the series, compound 7a-7i exhibited excellent activity (MIC = 1.6 µM) against H37Rv strain of M.tuberculosis. However, antibacterial screening data (in vitro) revealed a moderate inhibition for 6e-6 g and 7f-7 h against gram-positive bacteria (Bacillus subtilis) and 7a-7i against gram-negative bacteria with a MIC value of 25 µg/ml. While moderate activity was observed against fungal (C. neoformns and C. albicans) strains with MIC value of 25–200 µg/mL. Additionally, five compounds (7a, 7d-7f and 7 h) were further evaluated for their in vitro inhibitory activity against E-coli DNA gyrase. These compounds displayed significant inhibitory activity against the DNA gyrase enzyme with an IC50 value of 0.08 – 0.5 µM.

Synthesis of Novel Benzimidazole-Based Thiazole Derivatives as Multipotent Inhibitors of α-Amylase and α-Glucosidase: In Vitro Evaluation along with Molecular Docking Study.

In this study, hybrid analogs of benzimidazole containing a thiazole moiety (1–17) were afforded and then tested for their ability to inhibit α-amylase and α-glucosidase when compared to acarbose as a standard drug. The recently available analogs showed a wide variety of inhibitory potentials that ranged between 1.31 ± 0.05 and 38.60 ± 0.70 µM (against α-amylase) and between 2.71 ± 0.10 and 42.31 ± 0.70 µM (against α-glucosidase) under the positive control of acarbose (IC50 = 10.30 ± 0.20 µM against α-amylase) (IC50 = 9.80 ± 0.20 µM against α-glucosidase). A structure–activity relationship (SAR) study was carried out for all analogs based on substitution patterns around both rings B and C respectively. It was concluded from the SAR study that analogs bearing either substituent(s) of smaller size (−F and Cl) or substituent(s) capable of forming hydrogen bonding (−OH) with the catalytic residues of targeted enzymes enhanced the inhibitory potentials. Therefore, analogs 2 (bearing meta-fluoro substitution), 3 (having para-fluoro substitution) and 4 (with ortho-fluoro group) showed enhanced potency when evaluated against standard acarbose drug with IC50 values of 4.10 ± 0.10, 1.30 ± 0.05 and 1.90 ± 0.10 (against α-amylase) and 5.60 ± 0.10, 2.70 ± 0.10 and 2.90 ± 0.10 µM (against α-glucosidase), correspondingly. On the other hand, analogs bearing substituent(s) of either a bulky nature (−Br) or that are incapable of forming hydrogen bonds (−CH3) were found to lower the inhibitory potentials. In order to investigate the binding sites for synthetic analogs and how they interact with the active areas of both targeted enzymes, molecular docking studies were also conducted on the potent analogs. The results showed that these analogs adopted many important interactions with the active areas of enzymes. The precise structure of the newly synthesized compounds was confirmed using several spectroscopic techniques as NMR and HREI-MS.

Anion-Directed Synthesis of Core–Shell and Janus Hybrid Nanostructures

Hybrid nanoparticles show considerable promise with potential applications ranging across catalysis (including photocatalysis), energy conversion, and storage. A generalized synthetic procedure for hybrid nanoparticles is presented. The method offers the flexibility to drive the products toward different hybrid nanostructure morphologies merely via a change in the metal anion, under otherwise identical experimental conditions. Both Ag@CZTS (CZTS = Cu2ZnSnS4) core–shell nanoparticles and Ag2S-CZTS Janus nanoparticles, along with PbS and Au/AuAg hybrid analogues, are synthesized using this methodology, highlighting its versatility and translatability across different materials. The nucleation of the semiconductor is the critical determining step for the synthesis of a given hybrid product. Insight into the mechanism of growth for these two morphologies paves the way for the rational and generalized synthesis of hybrid nanoparticles.

New quinoline-based triazole hybrid analogs as effective inhibitors of α-amylase and α-glucosidase: Preparation, in vitro evaluation, and molecular docking along with in silico studies.

The 7-quinolinyl-bearing triazole analogs were synthesized (1d–19d) and further assessed in vitro for their inhibitory profile against α-amylase andα-glucosidase. The entire analogs showed a diverse range of activities having IC50 values between 0.80 ± 0.05 µM to 40.20 ± 0.70 µM (α-amylase) and 1.20 ± 0.10 µM to 43.30 ± 0.80 µM (α-glucosidase) under the positive control of acarbose (IC50 = 10.30 ± 0.20 µM) (IC50 = 9.80 ± 0.20 µM) as the standard drug. Among the synthesized scaffolds, seven scaffolds 12d, 10d, 8d, 9d, 11d, 5d, and 14d showed excellent α-amylase and α-glucosidase inhibitory potentials with IC50 values of 4.30 ± 0.10, 2.10 ± 0.10, 1.80 ± 0.10, 1.50 ± 0.10, 0.80 ± 0.05, 5.30 ± 0.20, and 6.40 ± 0.30 µM (against α-amylase) and 3.30 ± 0.10, 2.40 ± 0.10, 1.20 ± 0.10, 1.90 ± 0.10, 8.80 ± 0.20, 7.30 ± 0.40, and 5.50 ± 0.10 µM (against α-glucosidase), respectively, while the remaining 12 scaffolds 19d, 8d, 17d, 16d, 15d, 7d, 4d, 3d, 1d, 2d, 13d and 6 d showed less α-amylase and α-glucosidase inhibitory potentials than standard acarbose but still found to be active. Structure–activity connection studies also showed that scaffolds with electron-withdrawing groups like -Cl, -NO2, and -F linked to the phenyl ring had higher inhibitory potentials for -amylase and -glucosidase than scaffolds with -OCH3, -Br, and -CH3 moieties. In order to better understand their binding sites, the powerful scaffolds 11d and 9d were also subjected to molecular docking studies. The results showed that these powerful analogs provide a number of important interactions with the active sites of both of these targeted enzymes, including conventional hydrogen bonding, pi–pi stacking, pi–sulfur, pi–anion, pi–pi, pi–sigma, T-shaped, and halogen (fluorine). Furthermore, various techniques (spectroscopic), including 1H, 13C-NMR, and HREI-MS mass, were used to explore the correct structure of newly afforded hybrid scaffolds based on quinoline-bearing triazole ring.

New biologically potent benzimidazole‐based‐triazole derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors along with molecular docking study

AbstractA series of fifteen hybrid analogs (1–15) based on benzimidazole bearing triazole skeleton were synthesized and were evaluated for in vitro AChE and BuChE inhibition profile. All the newly afforded scaffolds showed moderate to good AChE and BuChE activity having IC50 values ranging from 0.40 ± 0.05 to 19.60 ± 0.40 μM against AChE and 1.50 ± 0.10 to 23.30 ± 0.50 μM against BuChE in comparison to Donepezil (IC50 = 0.016 ± 0.12 μM for AChE), (IC50 = 4.5 ± 0.11 μM for BuChE) as reference drug. It was concluded from structure–activity relationship (SAR) studies that scaffolds bearing groups of strong e‐withdrawing nature (–NO2, –F and –Cl) at different position of aryl ring were found to be potent inhibitors of both targeted AChE and BuChE enzymes. Therefore, compounds 7 (bearing para‐NO2), 2 (bearing para‐fluoro), 6 (bearing meta‐NO2) and 8 (bearing meta‐fluoro) were identified as the most active on screening against AChE enzyme with IC50 values of 0.40 ± 0.05, 0.60 ± 0.05 and 0.80 ± 0.05 and 0.90 ± 0.05 μM. These scaffolds 7, 2, 6 and 8 also showed superior potency against BuChE enzyme with IC50 values of 1.50 ± 0.10, 2.10 ± 0.10, 2.60 ± 0.10 and 2.30 ± 0.10 μM. It was also observed that inhibition profile of synthesized scaffolds against both these targeted enzymes was greatly affected by altering either position or number/s of substituent around aryl ring. Moreover, it was noteworthy that scaffolds that hold substituent of bulky nature are unable to interact better with active site of targeted enzymes and hence, lower the enzymatic potentials against targeted enzymes. In addition, the active scaffolds such as 7 and 2 were further subjected to molecular docking studies and result obtained revealed that these active scaffolds interacts well both with AChE and BuChE enzymes and forms several key interactions (conventional hydrogen bond, π‐cation, π‐π stacking, π‐π T‐shaped, π‐sulfur and π‐alkyl) with active site of these targeted enzymes. Furthermore, newly afforded scaffolds were characterized by using various spectroscopic tools such as HR‐EI‐MS, 13C NMR and 1HNMR spectroscopy.

Development of pyrimidine-cinnamamide hybrids as potential anticancer agents: A rational design approach

Pyrimidine is a privileged scaffold and part of many anti-cancer drugs, whereas cinnamamides are present in many natural products. The present work reports the rational design and synthesis of 26 novel pyrimidine and cinnamamide hybrid analogs with further optimization in the core structure. The synthesized derivatives were tested against K-562 (chronic myeloid leukemia), MV4–11 (acute myeloid leukemia), G361 (malignant melanoma), and HCC827 (lung adenocarcinoma) cell lines. Compounds 10j, 10m, 10r, and 10t displayed low micromolar potency against leukemia cell lines. 10 m and 10r were the most potent analogs against G361 and HCC827 cell lines. Subsequently, structure-activity relationship study was carried out and revealed the nitro substitution was unfavorable for the activity. Cellular effects of compounds 10j and 10t were studied in the most sensitive cell line K562. The compounds arrested the cell cycle in G2/M phases and induced caspase-independent cell death.

Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain

Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, 17, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC50 values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound 17 showed partial agonism (EC50 = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound 17 showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain.

Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2.

This study represents the design and synthesis of a new set of triazole-coumarin-glycosyl hybrids and their tetrazole hybrid analogues possessing various sugar moieties and modified analogues. All the newly synthesized derivatives were screened for their cytotoxic activities against a panel of human cancer cell lines. The coumarin derivatives 10, 13 and 15 derivatives revealed potent cytotoxic activities against Paca-2, Mel-501, PC-3 and A-375 cancer cell lines. These promising analogues were further examined for their inhibitory assessment against EGFR, VEGFR-2 and CDK-2/cyclin A2 kinases. The coumarin-tetrazole 10 displayed broad superior inhibitory activity against all screened enzymes compared with the reference drugs, erlotinib, sorafenib and roscovitine, respectively. The impact of coumarin-tetrazole 10 upon cell cycle and apoptosis induction was determined to detect its mechanism of action. Additionally, it upregulated the levels of casp-3, casp-7 and cytochrome-c proteins and downregulated the PD-1 level. Finally, molecular docking study was simulated to afford better rationalization and gain insight into the binding affinity between the promising derivatives and their targeted enzymes, which could be used as an optimum lead for further modification in the anticancer field.

Acidification behavior of mixtures of pork meat and wet texturized plant proteins in a minced model system.

The increasing use of wet texturized plant proteins as meat substitutes requires a characterization of their functional properties, especially in terms of pH-behavior when being mixed with meat proteins to create so-called hybrid products. In this study, a minced model system containing pork meat, curing salt, and various amounts (0-100wt%) of wet extruded proteins from pea (Pea I, II), pumpkin (Pumpkin I, II, III), and sunflower was used to evaluate the effect of mixing on pH and time-dependent pH-changes upon the addition of glucono-delta-lactone (GDL). Increasing concentrations of plant extrudates resulted in a linear increase of the initial (pH0h ), intermediate (pH6h ), and final pH48h for all samples and higher slopes at higher native pH of extrudates were found. Acidification kinetics of all samples were similar with a distinct pH-drop by 0.3 to 0.8pH-units per wt% GDL in the first 6h, followed by a plateau where pH remained constant. At extrudate concentrations of 5wt% (Pea I, II, Pumpkin I, II) or 15wt% (Pumpkin III, Sunflower), a sufficient acidification with typically used GDL-amounts ( =1wt%) could be achieved, while higher plant protein contents required higher GDL-concentrations in order to reach a pH value of 5.0; a common target value in dry-cured sausages. A mathematical model was proposed to correlate pH, time, acidifier, extrudate concentration, and plant protein origin, to aid in the adjustment of dry-cured hybrid meat formulations, and to describe thresholds of the feasible extrudate and acidifier concentrations. PRACTICAL APPLICATION: Despite the increasing relevance of texturized plant proteins as meat mimetics, little is known about their functional and process-related properties. This study shows that plant protein origin, the level of meat replacement, and the amount of acidifier are linked to the time-dependent pH-value on the basis of a mathematical model. This brings food developers one step closer in creating tailored formulations and estimating the effects of these novel ingredients in the final product characteristics of hybrid meats and analogues.

Structural based investigation of novel pyrazole-thiazole Hybrids as dual CDK-1 and CDK-2 inhibitors for cancer chemotherapy

ABSTRACT CDK-1 and CDK-2 are two promising targets for cancer treatment as they are vital in tumor development, proliferation, and apoptosis during the cell cycle process. In treating cancers, CDK inhibitors (small molecules) are used to prevent the overproliferation and overexpression of cancer cells. Consequently, inhibiting CDKs is a promising treatment strategy in oncology. The limitations imposed by current CDK-1 and CDK-2 inhibitors, including neurotoxicity and the development of resistance, have prompted our group to use the novel synthesized pyrazole-thiazole hybrid analogues to investigate their possible potency against CDK-1 and CDK-2. The research study employed detailed computational approaches including molecular docking, molecular dynamics (MD) simulations, post-MD analyses such as RMSD, RMSF, RoG, per-residue energy decomposition, hydrogen bond lifetime analysis, and drug-likeness studies like ADME properties prediction and cytotoxicity, to predict the properties and inhibitory potentials of synthesized pyrazole-thiazole hybrid analogues against CDK-1 and CDK-2. The in silico binding free energy and other analysis reported in the study revealed that four (7 g, 8a, 8b, and 8 h) of the tested molecules against CDK-1 demonstrated a higher binding affinity and structural influence on the target protein than the known inhibitor, Roscovitine (RVT). Similarly, in the case of CDK-2, four (7b, 8a, 8b, and 8f) of the tested compounds showed better results than (RVT). Furthermore, structural examination of the two proteins after binding to the inhibitors revealed that the compounds form stable complexes with the targets and significantly reduced the structural flexibility of the proteins. Therefore, this study suggests the novel pyrazole-thiazole hybrid analogues as potential CDK-1 and CDK-2 inhibitors and could be potential lead compounds for target-based anticancer drugs inhibiting the important proteins, CDK-1 and CDK-2.

Design, synthesis, biological evaluation and molecular modelling studies of oxoacetamide warhead containing indole-quinazolinone based novel hybrid analogues as potential pancreatic lipase inhibitors

A novel series of indolyl oxoacetamide-quinazolinone hybrid analogues (9aa–9df) were designed, synthesized, and evaluated for their in vitro pancreatic lipase (PL) inhibitory potential that may lead to efficient anti-obesity agents.

Efficient One-Pot Synthesis of Pyrazole–Pyrazol-3-one Hybrid Analogs and Evaluation of Their Antimicrobial Activity

Efficient One-Pot Synthesis of Pyrazole–Pyrazol-3-one Hybrid Analogs and Evaluation of Their Antimicrobial Activity